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Abstract  
Objectives: To study the association of genetic 
polymorphisms of coagulation factors with clinical 
and laboratory indicators in pregnant women with 
placental insufficiency with fetal growth retardation. 
Materials and methods: The study group included 250 
pregnant women with placental insufficiency with 
fetal growth retardation (FGR). The control group 
consisted of 247 women without FGR. The 
participants were genotyped for four genetic markers 
of hereditary thrombophilia: fibrinogen (-455G/A FI), 
prothrombin (20210G/A FII), factor V Leiden 
(1691G/A FV), proconvertin (10976G/A FVII). 
Results: In the group of pregnant women with FGR, 
having genotypes -455GA FI and -455AA FI, a higher 
level of fibrinogen (4.7 g/l) is observed compared to 
women with the genotype -455GG FI (4.5 g/l, 
p=0.04). Conclusion: Thus, the study conducted on the 
relationship of polymorphic locus -455G/A FI with a 
higher level of fibrinogen in pregnant women with 
fetal growth retardation. 
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Introduction 
Placental insufficiency is a syndrome caused by 
morphofunctional changes in the placenta, the 
progression of which develops a fetal growth 
retardation syndrome, often combined with hypoxia 
(Bamfo, Odibo, 2011, Zollner et al., 2011; Unanyan et 
al., 2015). Placental insufficiency (PI) is one of the 
most common complications of pregnancy (Serov et 
al., 2011; Diner et al., 2016). Perinatal mortality in 
women who underwent placental insufficiency is 
among the full-term newborns 10.3 %, among preterm 
infants – 49 % (Serov et al., 2011; Diner et al., 2016). 
In 60% of cases, placental insufficiency leads to the 
development of FGR, which ranks third in the 
structure of the causes of perinatal morbidity (Serov et 
al., 2011). Placental insufficiency has a multifactorial 
nature (Makacariya, Bicadze, 2006, Serov et al., 2011; 
Zollner et al., 2011). 
One of the factors leading to the development of 
placental insufficiency and FGR is hereditary 
thrombophilia (Zotz et al., 2008; Facco et al., 2009; 
Nishizawa et al., 2011; Kosar et al., 2011).  
But the results of these studies, obtained by different 
authors, are often contradictory (Camilleri et al, 2004; 
Infante-Rivard et al., 2005; Dudding et al., 2008; Zotz 
et al., 2008; Facco et al., 2009; Ivanov et al., 2009; 
Shanker et al., 2009; Kosar et al., 2011; Nishizawa et 
al., 2011; Coriu et al., 2014; Livrinova et al., 2015; 
Reshetnikov et al., 2017). 
 
Materials and Methods 
Object of Study 
In total 497 unrelated pregnant women in the third 
trimester of pregnancy were recruited for the study 
during 2009-2013. All participants signed an informed 
consent before entering the study. The clinical and 
laboratory examination of the participants was 
conducted in the perinatal center of the Saint Joasaph 
Belgorod Regional Clinical Hospital. The following 
inclusion criteria were used to check eligibility of the 
participants: singleton pregnancy, Russian ethnicity. 
Patients having congenital malformations of internal 
genitals, uterine fibroids, anomalies of placental 
location, isosensitization of Rh factor or ABO, genetic 
diseases, were excluded from the study.  
250 participants were diagnosed with the syndrome of 
fetal growth retardation of varying severity. The 
diagnosis of the syndrome was based on clinical data, 
ultrasound fetometry (TOSHIBA XARIO SSA-660A) 
and parameters of growth and weight after the birth. 
Based on the differences between the fetometric data 
and nomograms, three degrees of FGR were classified: 
1st degree corresponded to the reduction of the 
estimated gestational ages from the standard ones by 2 
weeks, 2nd degree – by 3-4 weeks, and 3rd degree – by 
more than 4 weeks. 
The controls were 247 females without the syndrome 
of intrauterine growth retardation.  
The laboratory study included a clinical blood test 
(with determination of the number of basic blood 
elements, hematocrit indicator); biochemical blood 
test (total protein, total bilirubin, urea, creatinine, level 
of hepatic aminotransferases, alkaline phosphatase, 
glucose); coagulogram (prothrombin index, activated 
partial thromboplastin time, thrombin time (TB), 
fibrinogen, international normalized ratio (INR), 
ethanol test, b-naphtholol test), extended study of 
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hemostatic system (detection of soluble fibrin 
monomer complexes), antithrombin-III, protein C and 
protein S, platelet aggregation tests); determination of 
blood type and Rh factor. Also, analyzes were 
performed to exclude the antiphospholipid syndrome 
(lupus anticoagulant, cardiolipin antibodies, 
antiphospholipid antibodies) and associated hereditary 
thrombophilia. 
 
Molecular and Genetic methods  
The participants were genotyped for four genetic 
markers of hereditary thrombophilia: fibrinogen (-
455G/A FI), prothrombin (20210G/A FII), factor V 
Leiden (1691G/A FV), proconvertin (10976G/A 
FVII). 
The material for the study was venous blood, obtained 
in a volume of 8-9 ml from the ulnar vein of pregnant 
women. All polymorphic variants of hereditary 
thrombophilia were analyzed using the method of 
polymerase chain reaction (PCR) of DNA synthesis in 
real-time (real-time-PCR).  
 
Statistical Methods  
The obtained genotypes were checked for their 
correspondence to the Hardy-Weinberg distribution 
(HWE) using the 2-test. Association of the 
polymorphisms with FGR was estimated by analyzing 
2×2 contingency tables with the χ2-test and the Yates’ 
correction for continuity. The risk was estimated using 
odds ratio with 95% confidence intervals (95% CI). 
The median (Me) and interquartile range (Q25-Q75) 
were used to describe the traits studied, and the Mann-
Whitney test for comparative analysis. The analyses 
were performed using STATISTICA 6.0 (StatSoft, 
USA). The Bonferroni correction was applied to adjust 
for multiple comparisons. 
 
Results  
Characteristics of pregnant women with FGR and 
control group are shown in Table 1.  
The analysis of clinical and laboratory parameters in 
pregnant women with FGR and control group was 
carried out: a general blood test, a biochemical blood 
test, a coagulogram, as well as the level of 
antithrombin III and soluble fibrin-monomer 
complexes (SFMC), a general urine test. The 
associations of genetic variants of coagulation factors 
with clinico-laboratory indicators in pregnant women 
with FGR and in the control group were studied. 
 
 
 
 
Table 1 Physical Characteristics and Various Medical 
Pathologies in the Study Participants 
 FRG 
patients,  
n (%) 
Controls, 
n (%) 
р 
N 250 247  
Age, y  
(min-max) 
26.78 ± 4.81 
(16.0-45.0) 
26.20 ± 
5.01 
(19.0-
41.0) 
>0.05 
BMI, kg/m2 23.37 ± 4.31 23.90 ± 
3.96 
>0.05 
Somatic Pathologies 
Essential 
Hypertension 
50 (20.00) 29 (11.74) 0.02 
Chronic 
Pyelonephritis 
63 (25.20) 55 (22.27) 0.51 
Obesity 23 (9.20) 22 (8.91) 1.00 
Varicose Veins 13 (5.20) 10 (4.05) 0.69 
Venous 
Thromboembolism 
at Pregnancy 
4 (1.60) 1 (0.41) 0.38 
Chronic 
Gastroduodenitis 
26 (10.40) 22 (8.89) 0.68 
Cerebrovascular 
Disease in History 
2 (0.80) 0 (0.0) 0.50 
Gynecological Pathologies 
Medical Abortion 
in History 
80 (32.00) 65 (26.32) 0.20 
Infertility in 
History 
5 (2.00) 8 (3.24) 0.56 
Miscarriage in 
History (Total)  
46 (18.40) 25 (10.12) 0.01 
Miscarriage in 
First Trimester  
36 (14.40) 20 (8.10) 0.04 
Pregnancy Loss in 
First Trimester  
12 (4.80) 12 (4.86) 1.00 
Ectopic Pregnancy 10 (4.00) 15 (6.07) 0.39 
Disorders of the 
Menstrual Cycle in 
History 
20 (8.00) 14 (5.67) 0.39 
Pelvic 
Inflammatory 
Disease in History 
58 (23.20) 59 (23.89) 0.94 
Intrauterine 
Infection During 
Pregnancy 
83 (33.20) 80 (32.39) 0.68 
Preeclampsia 55 (22.00) 68 (27.53) 0.19 
Antenatal 
Intrauterine Fetal 
Death 
4 (1.60) 0 0.14 
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As a result of the analysis, it was found that a 
statistically significant higher fibrinogen level was 
observed in the group of pregnant women with FGR 
having genotypes -455GA FI and -455AA FI (median 
– 4.7 g/l, interquartile range – 4.0-5.5 g/l) compared to 
with women with genotype -455GG FI (median 4.5 
g/l, interquartile range 4.0-5.1 g/l, p= 0.04). 
Other molecular genetic markers showed no 
significant associations with clinical and laboratory 
indicators in pregnant women. 
 
Discussion  
Our study showed that the genetic variants -455GA FI 
and -455AA FI are associated with an increased level 
of fibrinogen in pregnant women with fetal growth 
retardation. 
Fibrinogen is a plasma globulin consisting of three 
pairs of identical polypeptide chains: Aα-, Bβ- and γ. 
The sequences of the polypeptide chains of fibrinogen 
are encoded in three different genes located in the long 
arm of the chromosome 14. 
Several variants of gene polymorphism have been 
found, which are in total responsible for fluctuations 
in the level of fibrinogen in the range of 34-50% 
(Endler et al., 2003). The -455G/A polymorphism is 
associated with an increase in the level of fibrinogen 
(Makacariya, Bicadze, 2006). A high level of 
fibrinogen in the blood can indicate a high risk of 
thrombosis (Dyatlova et al., 2015; Makacariya, 
Bicadze, 2006). Hyperfibrinogenemia is observed in 
hypercoagulation and in the first stage of DIC-
syndrome (Dyatlova et al., 2015). 
Previously, researchers also established a relationship 
of polymorphism -455 G/A FI with a higher plasma 
fibrinogen level (Humphries et al., 1987; Makacariya, 
Bicadze, 2006; Yenicesu et al., 2010). On the contrary, 
in other works opposite results were obtained 
(Poursadegh Zonouzi et al., 2013). 
In our study, were found no significant associations of 
polymorphic loci 20210G/A FII, 1691G/A FV, 
10976G/A FVII with clinico-laboratory parameters in 
pregnant women with FGR. 
In other works, contradictory results were also 
obtained. 
Thus, several studies have shown the connection of 
polymorphism 10976G/A FVII with the level of 
proconvertin in plasma. The presence of the 
heterozygous variant 10976GA FVII was associated 
with a decrease in the concentration of factor VII in 
the blood by about 25%, and in the 10976AA FVII 
homozygote – with a factor concentration decrease of 
approximately 50% compared to the carriers of the 
variant 10976GG FVII (Makacariya et al., 2006, 
Seremak-Mrozikiewicz et al., 2009). 
Some researchers have identified associations of 
polymorphisms of 1691G/A FV and 20210G/A FII 
with the risk of developing FGR (Martinelli et al., 
2001; Dudding, Attia, 2004; Howley et al., 2005); in 
contrast, (Infante-Rivard et al., 2002). 
Thus, the conducted study on the relationship of 
polymorphic locus -455G/A FI with a higher level of 
fibrinogen in pregnant women with FGR. The elevated 
fibrinogen level associated with the carriage of 
genotypes -455GA FI and -455AA FI can serve as a 
marker of thrombophilia risk and the development of 
fetal development retardation syndrome. 
The obtained results broaden the concept of the role of 
hereditary thrombophilia in the development of fetal 
growth retardation and their use in practical obstetrics. 
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